Results 21 to 30 of about 283,567 (361)

Neutralizing antibodies in hepatitis C virus infection [PDF]

World Journal of Gastroenterology, 2007
Hepatitis C virus (HCV) is a major cause of hepatitis world-wide. The majority of infected individuals develop chronic hepatitis which can then progress to liver cirrhosis and hepatocellular carcinoma. Spontaneous viral clearance occurs in about 20%-30% of acutely infected individuals and results in resolution of infection without sequaelae. Both viral
Zeisel, Mirjam, Fafi-Kremer, Samira, Fofana, Isabel, Barth, Heidi, Stoll-Keller, Francoise, Doffoel, Michel, Baumert, Thomas   +6 more
openaire   +4 more sources

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge [PDF]

, 2016
End-stage liver disease caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation the liver graft of viremic patients universally becomes infected by circulating virus ...
Baumert, Thomas F., Cole, Sarah, Desombere, Isabelle, Fafi-Kremer, Samira, Farhoudi, Ali, Heydmann, Laura, Leroux-Roels, Geert, McKeating, Jane A., Meuleman, Philip, Patel, Arvind H., Pessaux, Patrick, Van Houtte, Freya, Verhoye, Lieven   +12 more
core   +3 more sources

Predicting the effectiveness of hepatitis C virus neutralizing antibodies by bioinformatic analysis of conserved epitope residues using public sequence data [PDF]

, 2018
Hepatitis C virus (HCV) is a global health issue. Although direct-acting antivirals are available to target HCV, there is currently no vaccine. The diversity of the virus is a major obstacle to HCV vaccine development. One approach toward a vaccine is to
Cowton, Vanessa M., Gifford, Robert J., Patel, Arvind H., Singer, Joshua B.   +3 more
core   +2 more sources

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report

Journal of Medical Case Reports, 2009
Introduction Pure red cell aplasia due to anti-epoetin antibodies is a known complication of epoetin therapy for anemia due to chronic kidney disease. This disease has not previously been well described in the setting of therapy for chronic hepatitis C ...
Behler Caroline M, Terrault Norah A, Etzell Joan E, Damon Lloyd E   +3 more
doaj   +1 more source

Prevalence of Hepatitis B and Hepatitis C Infections in a Tertiary Care Hospital, Telangana, India - Comparison of Pre-Pandemic and COVID-19 Pandemic times

Journal of Pure and Applied Microbiology, 2022
WHO estimates show that 296 million people were living with chronic hepatitis B infection in 2019 with 1.5 million new infections occurring every year and approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular ...
C. Roopa, Suryakiran Kamineni, Panthagani Narasimhulu Shilpa, Bheemathati Ranga Rao   +3 more
doaj   +1 more source

Expression in Escherichia coli of a cloned DNA sequence encoding the pre-S2 region of hepatitis B virus [PDF]

, 1985
A DNA sequence encoding the entire pre-S2 region (amino acids 120-174; serotype ayw) of human hepatitis B virus envelope protein has been inserted into the lacZ gene of the plasmid pSKS105 yielding a recombinant, pWS3.
Acs, George, Christman, Judith K., Kent, Stephen B. H., Neurath, A. Robert, Offensperger, Wolf, Price, Peter, Strick, Nathan, Wahl, Silke   +7 more
core   +1 more source

Performance study of the automated immunoassay test anti-hepatitis C virus VIDAS® for the qualitative detection of antibodies anti-hepatitis C virus

Microbiologia Medica, 2016
Background and aims: Hepatitis C virus (HCV) represents a major worldwide public health problem requiring global action for the diagnosis, treatment and prevention of this infection.
Sara Salvetti, Federica Lavinia, Iolanda Montenora   +2 more
doaj   +1 more source

Neutralizing Antibody Response to Hepatitis C Virus [PDF]

Viruses, 2011
A critical first step in a “rational vaccine design” approach for hepatitis C virus (HCV) is to identify the most relevant mechanisms of immune protection. Emerging evidence provides support for a protective role of virus neutralizing antibodies, and the ability of the B cell response to modify the course of acute HCV infection.
Zhen-Yong Keck, Yong Wang, Steven K. H. Foung   +2 more
openaire   +3 more sources

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. [PDF]

, 2009
Hepatitis C virus (HCV) entry occurs via a pH- and clathrin-dependent endocytic pathway and requires a number of cellular factors, including CD81, the tight-junction proteins claudin 1 (CLDN1) and occludin, and scavenger receptor class B member I (SR-BI).
Balfe, Peter, Grove, Joe, Hu, Ke, McKeating, Jane A, Mee, Christopher J, Schwarz, Anne K   +5 more
core   +2 more sources